vs
Abacus Global Management, Inc.（ABX）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是Abacus Global Management, Inc.的1.8倍（$127.1M vs $71.9M），Abacus Global Management, Inc.同比增速更快（116.5% vs 17.1%），Abacus Global Management, Inc.自由现金流更多（$-26.6M vs $-26.7M），过去两年Abacus Global Management, Inc.的营收复合增速更高（82.9% vs 20.8%）
Abacus集团是澳大利亚ASX 200指数成分公众上市公司，专注投资澳大利亚房地产投资信托，投资组合集中在写字楼与自助仓储领域，同时管理房地产开发的legacy投资项目。该公司原名为Abacus地产集团，2023年8月拆分出了自助仓储业务Abacus Storage King。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
ABX vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.8倍
$71.9M
营收增速更快
ABX
高出99.4%
17.1%
自由现金流更多
ABX
多$87.1K
$-26.7M
两年增速更快
ABX
近两年复合增速
20.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $71.9M | $127.1M |
| 净利润 | $7.2M | — |
| 毛利率 | 88.8% | 51.0% |
| 营业利润率 | 31.7% | -54.6% |
| 净利率 | 10.1% | — |
| 营收同比 | 116.5% | 17.1% |
| 净利润同比 | 139.6% | — |
| 每股收益（稀释后） | $0.06 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABXZLAB
| Q4 25 | $71.9M | $127.1M | ||
| Q3 25 | $63.0M | $115.4M | ||
| Q2 25 | $56.2M | $109.1M | ||
| Q1 25 | $44.1M | $105.7M | ||
| Q4 24 | $33.2M | $108.5M | ||
| Q3 24 | $28.1M | $101.8M | ||
| Q2 24 | $29.1M | $100.1M | ||
| Q1 24 | $21.5M | $87.1M |
净利润ABXZLAB
| Q4 25 | $7.2M | — | ||
| Q3 25 | $7.1M | $-36.0M | ||
| Q2 25 | $17.6M | $-40.7M | ||
| Q1 25 | $4.6M | $-48.4M | ||
| Q4 24 | $-18.3M | — | ||
| Q3 24 | $-5.1M | $-41.7M | ||
| Q2 24 | $770.0K | $-80.3M | ||
| Q1 24 | $-1.3M | $-53.5M |
毛利率ABXZLAB
| Q4 25 | 88.8% | 51.0% | ||
| Q3 25 | 87.8% | 59.5% | ||
| Q2 25 | 89.2% | 60.6% | ||
| Q1 25 | 83.9% | 63.6% | ||
| Q4 24 | 88.8% | 61.5% | ||
| Q3 24 | 92.2% | 64.1% | ||
| Q2 24 | 90.6% | 64.9% | ||
| Q1 24 | 87.3% | 61.4% |
营业利润率ABXZLAB
| Q4 25 | 31.7% | -54.6% | ||
| Q3 25 | 35.6% | -42.3% | ||
| Q2 25 | 40.1% | -50.3% | ||
| Q1 25 | 47.6% | -53.3% | ||
| Q4 24 | -50.5% | -62.6% | ||
| Q3 24 | 24.3% | -66.6% | ||
| Q2 24 | 23.3% | -76.0% | ||
| Q1 24 | 10.5% | -80.7% |
净利率ABXZLAB
| Q4 25 | 10.1% | — | ||
| Q3 25 | 11.2% | -31.2% | ||
| Q2 25 | 31.3% | -37.3% | ||
| Q1 25 | 10.5% | -45.8% | ||
| Q4 24 | -55.0% | — | ||
| Q3 24 | -18.2% | -40.9% | ||
| Q2 24 | 2.6% | -80.2% | ||
| Q1 24 | -6.3% | -61.4% |
每股收益（稀释后）ABXZLAB
| Q4 25 | $0.06 | $-0.05 | ||
| Q3 25 | $0.07 | $-0.03 | ||
| Q2 25 | $0.18 | $-0.04 | ||
| Q1 25 | $0.05 | $-0.04 | ||
| Q4 24 | $-0.26 | $-0.09 | ||
| Q3 24 | $-0.07 | $-0.04 | ||
| Q2 24 | $0.01 | $-0.08 | ||
| Q1 24 | $-0.02 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $38.1M | $689.6M |
| 总债务越低越好 | $405.8M | — |
| 股东权益账面价值 | $418.5M | $715.5M |
| 总资产 | $902.2M | $1.2B |
| 负债/权益比越低杠杆越低 | 0.97× | — |
8季度趋势，按日历期对齐
现金及短期投资ABXZLAB
| Q4 25 | $38.1M | $689.6M | ||
| Q3 25 | $86.4M | $717.2M | ||
| Q2 25 | $74.8M | $732.2M | ||
| Q1 25 | $43.8M | $757.3M | ||
| Q4 24 | $131.9M | $779.7M | ||
| Q3 24 | $19.4M | $616.1M | ||
| Q2 24 | $91.3M | $630.0M | ||
| Q1 24 | $65.4M | $650.8M |
总债务ABXZLAB
| Q4 25 | $405.8M | — | ||
| Q3 25 | $409.3M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $380.8M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ABXZLAB
| Q4 25 | $418.5M | $715.5M | ||
| Q3 25 | $434.6M | $759.9M | ||
| Q2 25 | $416.5M | $791.7M | ||
| Q1 25 | $430.6M | $810.8M | ||
| Q4 24 | $423.3M | $840.9M | ||
| Q3 24 | $257.9M | $667.7M | ||
| Q2 24 | $256.8M | $704.2M | ||
| Q1 24 | $165.3M | $762.2M |
总资产ABXZLAB
| Q4 25 | $902.2M | $1.2B | ||
| Q3 25 | $918.9M | $1.2B | ||
| Q2 25 | $848.4M | $1.2B | ||
| Q1 25 | $856.5M | $1.2B | ||
| Q4 24 | $874.2M | $1.2B | ||
| Q3 24 | $477.3M | $985.3M | ||
| Q2 24 | $483.9M | $987.4M | ||
| Q1 24 | $376.7M | $988.4M |
负债/权益比ABXZLAB
| Q4 25 | 0.97× | — | ||
| Q3 25 | 0.94× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.90× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-25.7M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $-26.6M | $-26.7M |
| 自由现金流率自由现金流/营收 | -37.0% | -21.0% |
| 资本支出强度资本支出/营收 | 1.3% | 0.5% |
| 现金转化率经营现金流/净利润 | -3.55× | — |
| 过去12个月自由现金流最近4个季度 | $-45.7M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流ABXZLAB
| Q4 25 | $-25.7M | $-26.0M | ||
| Q3 25 | $-32.8M | $-32.0M | ||
| Q2 25 | $76.1M | $-31.0M | ||
| Q1 25 | $-61.6M | $-61.7M | ||
| Q4 24 | $-208.8M | $-55.8M | ||
| Q3 24 | $-52.3M | $-26.8M | ||
| Q2 24 | $-67.1M | $-42.2M | ||
| Q1 24 | $2.5M | $-90.1M |
自由现金流ABXZLAB
| Q4 25 | $-26.6M | $-26.7M | ||
| Q3 25 | $-32.9M | $-35.0M | ||
| Q2 25 | $75.7M | $-33.9M | ||
| Q1 25 | $-61.8M | $-63.2M | ||
| Q4 24 | $-209.6M | $-58.4M | ||
| Q3 24 | $-52.5M | $-28.2M | ||
| Q2 24 | $-67.2M | $-42.9M | ||
| Q1 24 | $2.4M | $-91.1M |
自由现金流率ABXZLAB
| Q4 25 | -37.0% | -21.0% | ||
| Q3 25 | -52.3% | -30.4% | ||
| Q2 25 | 134.6% | -31.1% | ||
| Q1 25 | -140.0% | -59.9% | ||
| Q4 24 | -631.1% | -53.8% | ||
| Q3 24 | -186.6% | -27.7% | ||
| Q2 24 | -231.3% | -42.9% | ||
| Q1 24 | 10.9% | -104.5% |
资本支出强度ABXZLAB
| Q4 25 | 1.3% | 0.5% | ||
| Q3 25 | 0.3% | 2.6% | ||
| Q2 25 | 0.8% | 2.6% | ||
| Q1 25 | 0.5% | 1.5% | ||
| Q4 24 | 2.4% | 2.4% | ||
| Q3 24 | 0.9% | 1.3% | ||
| Q2 24 | 0.7% | 0.7% | ||
| Q1 24 | 0.8% | 1.1% |
现金转化率ABXZLAB
| Q4 25 | -3.55× | — | ||
| Q3 25 | -4.63× | — | ||
| Q2 25 | 4.33× | — | ||
| Q1 25 | -13.28× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -87.09× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABX
| Life Solutions Segment | $63.0M | 88% |
| Asset Management Segment | $8.7M | 12% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
